Covalon Receives Approval For Sale Of Its Three Wound Dressings In Canada.MISSISSAUGA, Ontario For the First Nation, see . Mississauga (pronounced: [ˌmɪsɪˈsɑgə] listen -- Covalon is extremely pleased to announce that it has received Health Canada Health Canada (French: Santé Canada) is the department of the government of Canada with responsibility for national public health. Health Canada's goal is to improve Canadian life by improving Canadian longevity, lifestyle and use of public healthcare. , Therapeutic Products Directorate Therapeutic Products Directorate (TPD) is a Canadian federal authority that regulates pharmaceutical drugs and medical devices for human use, a role performed by the Food and Drug Administration in the United States. , Medical Device licenses for three products: - ColActive Collagen wound dressing - ColActive Ag antimicrobial collagen wound dressing - CovaClear Ag antimicrobial collagen / hydrogel hy·dro·gel n. A colloidal gel in which the particles are dispersed in water. hydrogel a gel that contains water. hydrogel Wound care A polymer absorptive wound dressing. See Dressing. wound dressing The approval of these dressings for the Canadian market is an important milestone.Covalon can now expand sales by entering the Canadian acute care and chronic care markets, with an increased product offering across a greater range of treatment indications which include: -- Pressure ulcers -- Diabetic ulcers -- Ulcers caused by mixed vascular etiologies -- Venous ulcers -- First and Second degree burns -- Donor and graft sites -- Abrasions & lacerations -- Dehisced surgical wounds -- Traumatic wounds healing by secondary intention According to the 2000 Clinica Reports "New Developments in Wound Care ", the wound care market, world wide, exceeds $3.5 Billion US per year. It is estimated that the Canadian market for wound care is between $350 and $400 million. Covalon Technologies Ltd. is a company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility biocompatibility the quality of not having toxic or injurious effects on biological systems. biocompatibility 1. The extent to which a foreign, usually implanted, material elicits an immune or other response in a recipient 2. , and microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. attachment. The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion